NCT03925350View on ClinicalTrials.gov

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

PHASE2UnknownINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2023

Conditions
Metastatic Melanoma
Interventions
DRUG

Niraparib

300 mg PO daily

Trial Locations (1)

94115

RECRUITING

California Pacific Medical Center Research Institute, San Francisco

Sponsors
All Listed Sponsors
collaborator

Tesaro, Inc.

INDUSTRY

collaborator

Vanderbilt-Ingram Cancer Center

OTHER

collaborator

Huntsman Cancer Institute

OTHER

lead

California Pacific Medical Center Research Institute

OTHER